Case report reveals infliximab improves outcomes in a child with drug-induced hepatitis from tuberculosis treatment, highlighting a potential solution for refractory cases.
A 5-year-old child with tuberculous meningoencephalitis developed severe drug-induced hepatitis after conventional antitubercular therapy. Consequently, standard treatment was discontinued, and second-line drugs were administered in combination with high-dose corticosteroids. However, the disease continued to progress significantly. The introduction of infliximab resulted in substantial clinical and radiologic improvement, highlighting its potential role in managing refractory cases of central nervous system tuberculosis.
No takes yet. Share an insight, caveat, or question.
Barone et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: